ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

Cite this: ASCO 2025: Highlights in Prostate Cancer Biomarkers and Therapies - Medscape - June 06, 2025.

Marketing ASCO: J&J highlights Rybrevant-Lazcluze combo in 'Breathtaking Moments' lung cancer campaign high over Chicago skyline By Zoey Becker Jun 3, 2025 11:00am ...

Mario Campone, M.D., Ph.D., from the Institut de Cancérologie de l'Ouest Angers-Nantes in Saint-Herblain, France, and colleagues conducted a phase 3, open-label, randomized trial involving ...

FOSTER CITY, Calif., May 28, 2025--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology ...

But even if you don’t care about rival handhelds, SteamOS 3.7.8 has a lot of improvements for the Steam Deck. I’ve been asking Valve to let me use my Bluetooth earbuds’ microphone since ...

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines Aim is to provide quick access to consensus practices without noise of other AI systems Adobe ...

Preconference Considerations ASCO 2025: Previewing Updates in Metastatic Breast Cancer Dr McArthur is eager to attend the 2025 ASCO Annual Meeting, where key breast cancer studies will be ...

Valve says that the "SteamOS Compatible" label isn't meant to imply how well a game will run on the Steam Deck or any other SteamOS handheld but that this label is "just the first step." ...

ASCO 2025: The Latest in Cancer Research The ASCO annual meeting is widely considered one of the largest and most prestigious cancer research conferences in the world. From May 30 to June 3, more ...

Notable presentations at ASCO on Regeneron’s oncology pipeline include detailed efficacy and safety findings from the Phase 3 C-POST trial evaluating the adjuvant use of the PD-1 inhibitor ...